SCHEMBL22231968

SCHEMBL22231968

Cc1cc(N)c(Cl)c(N(C)c2cccc(F)c2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.37
ABCG2 Q9UNQ0 1/20 0.36
SLC6A2 P23975 4/20 0.33
SLC6A4 P31645 4/20 0.33
SLC6A3 Q01959 3/20 0.33
MAPK13 O15264 1/20 0.33
MAPK12 P53778 1/20 0.33
MAPK11 Q15759 1/20 0.33
MAPK14 Q16539 1/20 0.33
SNCA P37840 1/20 0.32
GPBAR1 Q8TDU6 1/20 0.32
CETP P11597 1/20 0.32
RAPGEF4 Q8WZA2 1/20 0.32
DHFR P00374 1/20 0.32
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
F2 P00734 1/20 0.31
F10 P00742 1/20 0.31
NOS2 P35228 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29454065 1.00 ACHE (0.37) ACHEABCG2SLC6A2SLC6A4SLC6A3
SCHEMBL31723215 1.00 ACHE (0.37) ACHEABCG2SLC6A2SLC6A4SLC6A3
SCHEMBL29454133 0.87 CSF1R (0.37) ACHEMAPK13MAPK12MAPK11MAPK14
SCHEMBL22232301 0.87 CSF1R (0.37) ACHEMAPK13MAPK12MAPK11MAPK14
SCHEMBL31723186 0.87 CSF1R (0.37) ACHEMAPK13MAPK12MAPK11MAPK14
SCHEMBL22232145 0.85 HTR3E (0.43) MAPK13MAPK12MAPK11MAPK14KMT2A
SCHEMBL31723251 0.85 HTR3E (0.43) MAPK13MAPK12MAPK11MAPK14KMT2A
SCHEMBL29454118 0.85 HTR3E (0.43) MAPK13MAPK12MAPK11MAPK14KMT2A
SCHEMBL31723220 0.85 NOS1 (0.32) SLC6A2SLC6A4SLC6A3NOS2
SCHEMBL29454059 0.85 NOS1 (0.32) SLC6A2SLC6A4SLC6A3NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US claimed
EP-3911629-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2021-11-24 EP claimed
WO-2020148617-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2020-07-23 WO claimed
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US disclosed
EP-3911629-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2021-11-24 EP disclosed
WO-2020148617-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2020-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF H1-3, PRMT7, PFAS ACHE 169/4885ABCG2 219/4885SLC6A2 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.